PDF herunterladen
Thromb Haemost 2013; 109(03): 560-563
DOI: 10.1160/TH12-08-0575
Letters to the Editor
Schattauer GmbH

Fondaparinux reversal with activated prothrombin complex concentrate in anesthetised bleeding rats

Gilles Corbonnois   *
1   University Hospital of Nancy, Department of Anaesthesia and Intensive Care Medicine, Nancy, France
2   INSERM 961, Contrat Avenir INSERM, Nancy, France
,
Michèle Martin   *
2   INSERM 961, Contrat Avenir INSERM, Nancy, France
3   University Hospital of Nancy, Haematology Laboratory – Haemostasis, Nancy, France
,
Marie Hacquard
3   University Hospital of Nancy, Haematology Laboratory – Haemostasis, Nancy, France
,
Bruno Levy
2   INSERM 961, Contrat Avenir INSERM, Nancy, France
4   Hospital University of Nancy, Intensive Care Medicine, Nancy, France
,
Paul Michel Mertes
1   University Hospital of Nancy, Department of Anaesthesia and Intensive Care Medicine, Nancy, France
1   University Hospital of Nancy, Department of Anaesthesia and Intensive Care Medicine, Nancy, France
,
Thomas Lecompte   **
2   INSERM 961, Contrat Avenir INSERM, Nancy, France
3   University Hospital of Nancy, Haematology Laboratory – Haemostasis, Nancy, France
5   Present address: Hôpitaux Universitaires de Genève, Service d’hématologie, Département académique de Médecine Interne, Faculté de médecine, UniGe, Genève, Switzerland
,
Gérard Audibert   **
1   University Hospital of Nancy, Department of Anaesthesia and Intensive Care Medicine, Nancy, France
2   INSERM 961, Contrat Avenir INSERM, Nancy, France
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 22. August 2012

Accepted after major revision: 26. Januar 2012

Publikationsdatum:
29. November 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

 

* Equal contribution as first authors.


** Equal contribution as supervisors.


 

  • References

  • 1 Kearon C, Akl EA, Comerota AJ. et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-494S.
    CrossrefPubMedGoogle Scholar
  • 2 Hamm CW, Bassand J-P, Agewall S. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
    CrossrefPubMedGoogle Scholar
  • 3 Bauer KA. Reversal of antithrombotic agents. Am J Hematol 2012; 87 (Suppl. 01) S119-126.
    CrossrefPubMedGoogle Scholar
  • 4 Bianchini EP, Fazavana J, Picard V. et al. Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 2011; 117: 2054-2060.
    CrossrefPubMedGoogle Scholar
  • 5 Lisman T, Bijsterveld NR, Adelmeijer J. et al. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. J Thromb Haemost 2003; 1: 2368-2373.
    CrossrefPubMedGoogle Scholar
  • 6 Gerotziafas GT, Depasse F, Chakroun T. et al. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004; 91: 531-537.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Desmurs-Clavel H, Huchon C, Chatard B. et al. Reversal of the inhibitory effect of fondaparinux on thrombin generation by rFVIIa, aPCC and PCC. Thromb Res 2009; 123: 796-798.
    CrossrefPubMedGoogle Scholar
  • 8 Bijsterveld NR, Moons AH, Boekholdt SM. et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
    CrossrefPubMedGoogle Scholar
  • 9 Elg M, Carlsson S, Gustafsson D. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits. Thromb Res 2001; 101: 159-170.
    CrossrefPubMedGoogle Scholar
  • 10 Ryan KL, Cortez DS, Dick EJ. et al. Efficacy of FDA-approved hemostatic drugs to improve survival and reduce bleeding in rat models of uncontrolled hemorrhage. Resuscitation 2006; 70: 133-144.
    CrossrefPubMedGoogle Scholar
  • 11 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
    CrossrefPubMedGoogle Scholar
  • 12 Hacquard M, Perrin J, Lelievre N. et al. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography. Thromb Res 2011; 127: 29-34.
    CrossrefPubMedGoogle Scholar
  • 13 Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001; 101: 145-157.
    CrossrefPubMedGoogle Scholar
  • 14 Dickneite G. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation. Thromb Res 2007; 119: 643-651.
    CrossrefPubMedGoogle Scholar
  • 15 Staszyk C, Bohnet W, Gasse H, Hackbarth H. Blood vessels of the rat tail: a histological re-examination with respect to blood vessel puncture methods. Lab Anim 2003; 37: 121-125.
    CrossrefPubMedGoogle Scholar
  • 16 Smogorzewska A, Brandt JT, Chandler WL. et al. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006; 130: 1605-1611.
    PubMedGoogle Scholar
  • 17 Gatt A, van Veen JJ, Woolley AM. et al. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost 2008; 100: 350-355.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 18 Crowther MA, Warkentin TE. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 2008; 111: 4871-4879.
    CrossrefPubMedGoogle Scholar
  • 19 Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10 (Suppl. 02) 10-16.
    CrossrefPubMedGoogle Scholar
  • 20 Turecek PL, Váradi K, Schwarz HP. Update on the mechanism of action and future of activated prothrombin complex concentrates. Curr Hematol Rep 2004; 3: 331-337.
    PubMedGoogle Scholar
  • 21 Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008; 14: 39-43.
    CrossrefPubMedGoogle Scholar
  • 22 Nagler M, Haslauer M, Wuillemin WA. Fondaparinux - data on efficacy and safety in special situations. Thromb Res 2012; 129: 407-417.
    CrossrefPubMedGoogle Scholar
  • 23 Huvers F, Slappendel R, Benraad B. et al. Treatment of postoperative bleeding after fondaparinux with rFVIIa and tranexamic acid. Neth J Med 2005; 63: 184-186.
    PubMedGoogle Scholar
  • 24 Luporsi P, Chopard R, Janin S. et al. Use of recombinant factor VIIa (NovoSeven®) in 8 patients with ongoing life-threatening bleeding treated with fondaparinux. Acute Card Care 2011; 13: 93-98.
    CrossrefPubMedGoogle Scholar
  • 25 Godier A, Durand M, Emmerich J. et al. Efficacy of prothrombin complex concentrate to reverse the anticoagulant effect of the pentasaccharide fondaparinux in a rabbit model. Thromb Haemost 2011; 105: 161-168.
    Artikel in Thieme ConnectPubMedGoogle Scholar